LABA/ICS Dosing Frequency for Moderate Asthma

Standard Twice-Daily Dosing

• The National Asthma Education and Prevention Program (NAEPP) guidelines recommend ICS-LABA combinations as daily controller therapy for moderate to severe persistent asthma, with standard administration being twice daily 1, 2, 3
• The NAEPP guidelines apply to all commonly used LABA/ICS combinations, including fluticasone/salmeterol and mometasone/formoterol, which should be administered twice daily 4

Alternative Regimen: ICS-Formoterol as Maintenance and Reliever

• The NAEPP Expert Panel strongly recommends ICS-formoterol in a single inhaler used as both daily controller (twice daily) and reliever therapy (as-needed for symptoms) for patients aged 4 years and older with moderate to severe persistent asthma, with high certainty of evidence 1, 2, 3, 5
• ICS-formoterol reduces severe exacerbations compared to same-dose ICS-LABA as fixed twice-daily therapy plus SABA for rescue 1, 2

Critical Safety Consideration

• The National Asthma Education and Prevention Program (NAEPP) and other guidelines emphasize that LABAs must never be used as monotherapy for asthma, and should only be used in combination with ICS therapy 4, 6

Practical Dosing Algorithm

• The American Thoracic Society and other organizations recommend starting with low-to-medium dose ICS-LABA twice daily (e.g., fluticasone/salmeterol 250/50 mcg or budesonide/formoterol 160/4.5 mcg, two inhalations twice daily) for moderate persistent asthma in patients ≥12 years 1
• Monitoring for increasing SABA use (>2 days/week for symptom relief) is crucial, as it indicates inadequate control requiring treatment intensification 6, 7